1 / 71

CEFAXIMIN-L

CEFACETRILE. First-generation CephalosporinMarked activity against Gram bacteria The major agents of bovine mastitis are very sensitive to its action (Streptococcus agalactiae, non-agalactiae streptococci, Staphylococcus aureus and CNS ) Also pretty active against E. coli and Klebsiella pneum

tyme
Download Presentation

CEFAXIMIN-L

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    2. CEFAXIMIN-L Particularly active against mastitic bacteria Diphasic action on both the galactophorous system and the mammary parenchyma High efficacy in acute and chronic mastitis Two formulations, three packs and complete with disposable towels and cow markers

    3. CEFACETRILE First-generation Cephalosporin Marked activity against Gram + bacteria The major agents of bovine mastitis are very sensitive to its action (Streptococcus agalactiae, non-agalactiae streptococci, Staphylococcus aureus and CNS ) Also pretty active against E. coli and Klebsiella pneumoniae

    4. CEFACETRILE

    5. CEFACETRILE Cephalosporins possess a common active nucleus (7-aminocephalosporanic acid) with different side-chains Common mechanism of action throughout the class and with the penicillins (?-lactam compounds): altered synthesis of the bacterial cell wall They are similar to penicillins in structure, but in general, can treat a broader range of infections and have greater beta-lactamase resistance

    6. CEFACETRILE: MECHANISM OF ACTION

    7. THE CELL WALL

    8. THE CELL WALL

    9. THE CELL WALL

    10. SYNTHESIS OF THE CELL WALL

    11. CEFACETRILE: MECHANISM OF ACTION

    12. CEFACETRILE: MECHANISM OF ACTION

    13. CEFACETRILE: MECHANISM OF ACTION

    14. CEFACETRILE: RESISTANCE

    15. -LACTAM ANTIBIOTICS AND AFFINITY WITH -LACTAMASES

    16. -LACTAM ANTIBIOTICS AND AFFINITY WITH -LACTAMASES

    17. CEFACETRILE: RESISTANCE

    18. CEFACETRILE: RESISTANCE

    19. CEFACETRILE: SPECTRUM OF ACTION

    20. CEFACETRILE: PHARMACOKINETICS

    21. CEFACETRILE: PHARMACOKINETICS

    22. RIFAXIMIN

    23. RIFAXIMIN: MECHANISM OF ACTION

    24. RIFAXIMIN : SPECTRUM OF ACTION

    25. RIFAXIMIN: RESISTANCE

    26. RIFAXIMIN: PHARMACOKINETICS

    27. RIFAXIMIN: PHARMACOKINETICS

    28. RIFAXIMIN: PHARMACOKINETICS

    29. THE CEFACETRILE-RIFAXIMIN ASSOCIATION

    30. DIPHASIC THERAPY Synergism of antibacterial activity Synergism of pharmacokinetic characteristics

    31. SYNERGISM OF ANTIBACTERIAL ACTIVITY

    32. SYNERGISM OF ANTIBACTERIAL ACTIVITY The MICs of the associated antibiotics and of these considered individually indicate that CEFAXIMIN potentiates the activity: of Cefacetrile from 2.5 to 34 times of Rifaximin from 1.5 to 9 times The most positive results are obtained against S. aureus and S. agalactiae

    33. SYNERGISM OF PHARMACOKINETICS

    34. SYNERGISM OF PHARMACOKINETICS

    36. CEFAXIMIN-L OINTMENT Permits a gradual distribution of the active substance to all areas of the udder, owing to the vehicle being highly soluble in milk SPRAY Obviates any occlusions of inflammatory nature, permitting rapid and capillary penetration

    37. CEFAXIMIN-L OINTMENT

    38. THE VEHICLE Complete tolerance demonstrated both in healthy animals and in animals with mastitis Studied to favour immediate high release of the active substances (over 80% within the first 12 hours after treatment)

    39. THE TWINSERT

    40. THE TWINSERT

    41. THE TWINSERT

    42. INDICATIONS

    43. DOSAGES

    44. INSTRUCTIONS FOR USE

    45. CEFAXIMIN-L OINTMENT

    46. ADVANTAGES OF CEFAXIMIN-L OINTMENT

    47. CEFAXIMIN-L SPRAY

    48. THE VEHICLE Specific excipients and inert gases formulated to produce rapid high release of the active substances (over 80% within the first 12 hours after treatment) The gaseous vehicle produces a fine atomisation in foam form of the antibiotic association, allowing uniform and deep distribution even to alveolar structures which are inaccessible to other commonly-used preparations

    49. INDICATIONS Streptococci (Str. agalactiae, Str. uberis, Str. dysgalactiae, Streptococcus. Sp.) Staphylococci (Staph. aureus - including penicillin-resistant strains CNS ) Corynebacteria (C. pyogenes) Coliforms (E. coli, Klebsiella, Enterobacter, Proteus, Serratia) Pseudomonads (Pseudomonas

    50. DOSAGES

    51. INSTRUCTIONS FOR USE

    52. CEFAXIMIN-L SPRAY

    53. ADVANTAGES OF CEFAXIMIN-L SPRAY

    54. ADVANTAGES OF CEFAXIMIN-L SPRAY

    55. ADVANTAGES OF CEFAXIMIN-L SPRAY

    56. CEFAXIMIN-L: THERAPEUTIC SYSTEM

    57. CLINICAL TRIALS

    58. CLINICAL TRIALS

    59. TOTAL CLINICAL RECOVERY

    60. CLINICAL RECOVERY IN THE VARIOUS FORMS OF MASTITIS

    61. RECOVERY RATE IN SUBCLINICAL MASTITIS ON THE BASIS OF A REDUCTION IN THE CELL COUNT

    62. NEGATIVE BACTERIAL TEST IN MASTITIS OF DIFFERENT ETIOLOGIES

    64. CLINICAL STUDY: OBJECTIVES To develop and evaluate an antibiotic treatment to control intramammary Staphylococcus aureus infections in dairy cows under field conditions On the basis of their in vitro sensitivity testing, pharmacokinetic properties and previous clinical trials, Rifaximin and Cefacetrile were chosen

    65. S. AUREUS SUSCEPTIBILITY TO TESTED ANTIBIOTICS

    66. CLINICAL STUDY: MATERIALS AND METHODS

    67. CLINICAL STUDY: MATERIALS AND METHODS

    68. THERAPEUTIC PROTOCOL

    69. REDUCTION OF STAPH. AUREUS PREVALENCE AND SCC

    70. REDUCTION OF STAPH. AUREUS PREVALENCE AND SCC

    71. CLINICAL STUDY: RESULTS

More Related